In a patient who develops urticaria after five days of anti‑tuberculosis therapy, which drug is most likely responsible and how should it be managed?

Rifampicin is the most likely culprit for urticaria after 5 days of ATT

All anti-tuberculosis drugs can cause rash, but rifampicin is the most common offender for urticaria developing within the first week of treatment, followed by pyrazinamide. 1 Recent large cohort data confirms that pyrazinamide is frequently implicated (48.1% of hypersensitivity cases), though the timing and pattern of your patient's presentation (urticaria at day 5) is most consistent with rifampicin 2.

Management Algorithm

Immediate Actions

1. Stop all ATT drugs immediately when urticaria develops 1

   • Do not attempt to continue through mild reactions
   • Document the exact timing and severity of the reaction

2. Provide symptomatic treatment:

   • High-dose H1-antihistamines (2-4 times standard daily dose) 3
   • Consider systemic corticosteroids if severe or progressive
   • Monitor for progression to Stevens-Johnson syndrome or DRESS (watch for fever, eosinophilia, systemic symptoms) 4

Identifying the Culprit Drug

Once urticaria resolves (typically 24-72 hours), perform sequential drug rechallenge 5:

The British Thoracic Society guideline provides the gold standard approach:

• Start with isoniazid: 50 mg/day, increase to 300 mg/day over 2-3 days if no reaction
• Add rifampicin: 75 mg/day, increase to 300 mg after 2-3 days, then to full dose (450-600 mg based on weight) over another 2-3 days
• Finally add pyrazinamide: 250 mg/day, increase to 1.0 g after 2-3 days, then to full dose (1.5-2 g based on weight)
• Ethambutol can be added throughout as it's least likely to cause urticaria

Monitor daily during rechallenge - both clinical condition and consider eosinophil counts 4

Alternative Interim Regimen

If the patient is smear-positive or clinically unwell and cannot wait for rechallenge 5:

• Use streptomycin + ethambutol as temporary coverage
• Check renal function before starting
• This maintains some anti-TB activity while identifying the culprit

If Rechallenge Confirms the Offending Drug

If rifampicin causes the reaction:

• Continue with isoniazid + pyrazinamide + ethambutol + fluoroquinolone
• Extend treatment duration to 9-12 months
• Consider desensitization if rifampicin is absolutely necessary (though success rates for urticaria are lower than for other reactions) 2

If pyrazinamide is the culprit 5:

• Continue rifampicin + isoniazid for 9 months
• Add ethambutol for initial 2 months
• This is a well-established alternative regimen

Critical Pitfalls to Avoid

1. Do not restart all drugs simultaneously - you will not identify the culprit and risk repeated reactions 6

2. Do not use systemic steroids alone without stopping ATT - this can lead to disease progression and mask ongoing reactions 6, 4

3. Type I reactions (77.7% of cases, including urticaria) have better outcomes than Type IV reactions - your patient should tolerate rechallenge well 7, 2

4. Female patients, older age, and history of other drug allergies increase risk - but do not change the management approach 7, 2

5. Most reactions occur in the first 2 months of treatment - heightened vigilance during this period is essential 2

Expected Outcome

With proper rechallenge protocol, over 90% of patients successfully complete ATT despite initial hypersensitivity reactions 2. The key is systematic identification of the culprit drug and appropriate regimen modification. Treatment success rates are actually higher in patients who develop and properly manage hypersensitivity compared to those who don't, likely due to closer monitoring 2.